<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234350</url>
  </required_header>
  <id_info>
    <org_study_id>FE200486 CS39</org_study_id>
    <nct_id>NCT01234350</nct_id>
  </id_info>
  <brief_title>A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON</brief_title>
  <official_title>A Prospective Observational Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON (Degarelix) or a GnRH Agonist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a large observational study, set-up to observe how long-term treatment with
      FIRMAGON (hormone regulator) compare to other treatments in regards to cardiovascular events,
      changes in bone density, changes in blood sugar levels or liver enzyme levels in subjects
      with prostate cancer. Subjects will be treated according to their routine clinical care and
      not dictated by the study. As the study is observational in nature, the study will collect
      data relating to the events specified above. Subjects that agree to this study will be
      followed-up for 5 years. Subject data will be collected every 3 months for the first 2 years
      and every 6 months for the last 3 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 27, 2018</completion_date>
  <primary_completion_date type="Actual">March 27, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Rate of Adverse Events of Special Interest (AESI): Cardiovascular Events</measure>
    <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
    <description>The incidence rate (IR) expressed as number of events per 100 patient-years of exposure (PYE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence Rate of AESI: Decreased Bone Density</measure>
    <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
    <description>IR of osteoporosis or osteopenia and bone fracture events are presented. The IR is expressed as number of events per 100 PYE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence Rate of AESI: Glucose Intolerance or Type 2 Diabetes Mellitus (T2DM)</measure>
    <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
    <description>IR of new onset or exacerbation of glucose intolerance or T2DM were presented. The IR expressed as number of events per 100 PYE.
Glucose intolerance events were defined as events of levels of fasting glucose of 6.1 to 6.9 mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hepatic Enzymes</measure>
    <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
    <description>Change from baseline in hepatic enzyme levels (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and alkaline phosphatase [ALP]) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hepatic Enzymes</measure>
    <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
    <description>Change from baseline in hepatic enzyme level (bilirubin) is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Glucose</measure>
    <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
    <description>Change from baseline in serum glucose are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Classification of New Adverse Drug Reactions (ADRs)</measure>
    <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
    <description>An ADR was defined as an AE assessed by investigator as possibly/probably related to the investigational product. Any new potentially unrecognized ADRs were presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long Term Evaluation of Clinical Evolution of Prostate Cancer</measure>
    <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
    <description>Change in prostate specific antigen (PSA) is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Testosterone Levels</measure>
    <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
    <description>Change from baseline in testosterone levels are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause of Mortality</measure>
    <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
    <description>A summary of IRs of all-cause mortality is presented.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1493</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>FIRMAGON</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRH Agonist</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with prostate cancer from primary care
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with prostate cancer and indicated for androgen deprivation therapy (ADT)

          -  Decision made to prescribe ADT prior to enrolment

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Participation in an interventional clinical study in which any treatment or follow-up
             is mandated

          -  Treatment with a GnRH receptor antagonist other than FIRMAGON

          -  Had previous or is currently under hormonal management of prostate cancer, except for
             subjects who have undergone therapy with curative intention where neoadjuvant/adjuvant
             therapy allowed for maximum 6 months. Treatment should be terminated at least 6 months
             prior to baseline.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan AV</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux IRIS Sud</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Université Catholique de Louvain</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Bruxelle</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Blasius</name>
      <address>
        <city>Dendermonde</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Jan Palfijn</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Lucas</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Jan Yperman VZW</name>
      <address>
        <city>Ieper</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge - Campus Sint-Maarten</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan</name>
      <address>
        <city>Oostende</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ-Sint-Elizabeth VZW</name>
      <address>
        <city>Zottegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Sygehus</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fredericia Hospital, Sygehus Lillebaelt</name>
      <address>
        <city>Fredericia</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holstebro Sygehus</name>
      <address>
        <city>Holstebro</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Kobenhavn</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionhospitalet Viborg</name>
      <address>
        <city>Viborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Docrates clinic</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pohjois-Karjalan keskussairaala</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seinäjoen keskussairaala</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopistollinen sairaala</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turun yliopistollinen keskussairaala</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peijaksen sairaala</name>
      <address>
        <city>Vantaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Athis Mons site Caron</name>
      <address>
        <city>Athis Mons</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Aubervilliers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Rhone Durance</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Jacques</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Laennec</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramsay Sante</name>
      <address>
        <city>Evry</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupement hospitalier Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical 65 prado</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Conception</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Saint-Jean</name>
      <address>
        <city>Melun</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Pont de Chaume</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Beausoleil</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Urologie de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Max Fourestier</name>
      <address>
        <city>Nanterre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Georges Renon</name>
      <address>
        <city>Niort</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalo-universitaire Caremeau</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Ter</name>
      <address>
        <city>Ploemeur</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic De L'Europe</name>
      <address>
        <city>Pontoise</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Michel</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique St Jean Languedoc</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres Effert und Benedic</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Schlichter</name>
      <address>
        <city>Bad Bergzabern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Markus Hentschel</name>
      <address>
        <city>Bautzen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Richter</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie im Schlosscarree</name>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Ahmad Haider</name>
      <address>
        <city>Bremerhaven</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Krieger</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie Chemnitz</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis fur Urologie</name>
      <address>
        <city>Dachau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikpraxis fur Urologie</name>
      <address>
        <city>Dinslaken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Schönfelder</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Urologie</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinshaftspraxis Rudolph &amp; Wörner</name>
      <address>
        <city>Kirchheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Thomas Harms</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vituro</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Alexander von Keitz</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Peczat</name>
      <address>
        <city>Nienburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum München-Planegg</name>
      <address>
        <city>Planegg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Reutlingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Jan Franz</name>
      <address>
        <city>Tostedt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis fur Urologie</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Agios Savas&quot; Anticancer-Oncology Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;G. Gennimtas&quot; General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Laiko&quot; General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amalia Fleming General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Errikos Dynan Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eurokliniki Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evaggelismos General Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Ag. Olga&quot; - Konstantopouleion</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ippokrateio Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korgialenio-Benakio</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pe. Pa.G.N:I Hospital</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General hospital of Kalamata</name>
      <address>
        <city>Kalamata</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IASO General Hospital</name>
      <address>
        <city>Kalamata</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aghios Andreas General Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <zip>Greece</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Piraeus &quot;Tzanneio&quot;</name>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;G. Gennimtas&quot; General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd IKA-ETAM &quot;Panagia&quot; General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papageorgiou General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Volos &quot;Achillopouleio&quot;</name>
      <address>
        <city>Volos</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azarka Zsuzsanna és Társa Bt</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UROFOR Bt</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiskunhalasi Semmelweis Kórház Kht.</name>
      <address>
        <city>Kiskunhalas</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miskolci Semmelweis Ignác Egészségügyi Központ és Egyetemi Oktató Kórház Nonprofit Kft</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uro-Clin Kft</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FEjér Megyei Szent György Kórhaz</name>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beacon Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Consulting Center S.r.l.</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Regionale del Molise (ASREM)</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Mater Domini di Catanzaro</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Carlo Poma</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Sacco</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Monaldi</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale Salerno</name>
      <address>
        <city>Nocera Inferiore</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori &quot;Regina Elena&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria OO.RR. S.Giovanni di Dio e Ruggi d'Aragona</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL 4 di Teramo</name>
      <address>
        <city>Teramo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;San Pio da Pietrelcina&quot;</name>
      <address>
        <city>Vasto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diaconessenhuis Leiden</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vestre Viken HF, Sykehuset Asker og Baerum</name>
      <address>
        <city>Asker</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helse Nordmore og Romsdal HF, Kristiansund Sykehus</name>
      <address>
        <city>Kristiansund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olso Universitetssykehus HF, Radiumhospitalet</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus, Aker</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Santo Antonio</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Militar</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VEBMED, s.r.o.</name>
      <address>
        <city>Bosany</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CUIMED, s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnica Svateho Michala, a.s.</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>URO clinic, s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinika Galanta</name>
      <address>
        <city>Galanta</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICONA s.r.o.</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UROCENTRUM LEVICE, s.r.o.</name>
      <address>
        <city>Levice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinika Malacky</name>
      <address>
        <city>Malacky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Martin</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UROEXAM, spol. s r.o.</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENTRUM UROLOGIE Povazska Bystrica s.r.o</name>
      <address>
        <city>Povazska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MILAB, s.r.o.</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UROCENTRUM SALA, s.r.o.</name>
      <address>
        <city>Sala</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnica s poliklinikou Skalica, a.s.</name>
      <address>
        <city>Skalica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M &amp; M &amp; M, s.r.o.</name>
      <address>
        <city>Topolcany</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRIVATNA UROLOGICKA AMBULANCIA s.r.o.</name>
      <address>
        <city>Trencin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UROREX, s.r.o.</name>
      <address>
        <city>Vrable</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urozentrum Zürich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homerton University Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whipps Cross Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Surrey Hospital</name>
      <address>
        <city>Redhill</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital</name>
      <address>
        <city>Sunderland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <results_first_submitted>February 21, 2019</results_first_submitted>
  <results_first_submitted_qc>February 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2019</results_first_posted>
  <last_update_submitted>June 14, 2019</last_update_submitted>
  <last_update_submitted_qc>June 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 1, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT01234350/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 8, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT01234350/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 136 sites in 15 European countries (Belgium, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Norway, Portugal, Slovakia, Switzerland, United Kingdom) recruited subjects to this observational study between January 2011 to April 2013, and the last subject completed the last visit in March 2018.</recruitment_details>
      <pre_assignment_details>A total of 1,515 subjects were screened, of which 1,493 subjects were found to be eligible and exposed to treatment; 1,000 subjects in the FIRMAGON group and 493 subjects in the gonadotrophin releasing hormone (GnRH) agonist group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FIRMAGON</title>
          <description>FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label</description>
        </group>
        <group group_id="P2">
          <title>GnRH Agonist</title>
          <description>Any GnRH agonist prescribed in accordance with the approved labels</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1000"/>
                <participants group_id="P2" count="493"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="687"/>
                <participants group_id="P2" count="267"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="277"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Covers a diverse set of reasons</title>
              <participants_list>
                <participants group_id="P1" count="234"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in androgen deprivation therapy [ADT], or end-of-study visit, whatever came first).</population>
      <group_list>
        <group group_id="B1">
          <title>FIRMAGON</title>
          <description>FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label</description>
        </group>
        <group group_id="B2">
          <title>GnRH Agonist</title>
          <description>Any GnRH agonist prescribed in accordance with the approved labels</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1000"/>
            <count group_id="B2" value="493"/>
            <count group_id="B3" value="1493"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Number analyzed differs from the overall population as age was not recorded for some of the subjects.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="999"/>
                    <count group_id="B2" value="493"/>
                    <count group_id="B3" value="1492"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.9" spread="8.33"/>
                    <measurement group_id="B2" value="73.2" spread="8.27"/>
                    <measurement group_id="B3" value="72.4" spread="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1000"/>
                    <count group_id="B2" value="493"/>
                    <count group_id="B3" value="1493"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1000"/>
                    <measurement group_id="B2" value="493"/>
                    <measurement group_id="B3" value="1493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Ethnicity was not recorded for some subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="780"/>
                    <count group_id="B2" value="385"/>
                    <count group_id="B3" value="1165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="697"/>
                    <measurement group_id="B2" value="353"/>
                    <measurement group_id="B3" value="1050"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Number analyzed differs from the overall population as race was not recorded for some of the subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="780"/>
                    <count group_id="B2" value="385"/>
                    <count group_id="B3" value="1165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="745"/>
                    <measurement group_id="B2" value="360"/>
                    <measurement group_id="B3" value="1105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2)</title>
          <population>Number analyzed differs from the overall population as baseline body mass index (BMI) was not calculated for some of the subjects.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="786"/>
                    <count group_id="B2" value="406"/>
                    <count group_id="B3" value="1192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="3.91"/>
                    <measurement group_id="B2" value="26.8" spread="3.82"/>
                    <measurement group_id="B3" value="26.9" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of Adverse Events of Special Interest (AESI): Cardiovascular Events</title>
        <description>The incidence rate (IR) expressed as number of events per 100 patient-years of exposure (PYE).</description>
        <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
        <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
        <group_list>
          <group group_id="O1">
            <title>FIRMAGON</title>
            <description>FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label</description>
          </group>
          <group group_id="O2">
            <title>GnRH Agonist</title>
            <description>Any GnRH agonist prescribed in accordance with the approved labels</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Adverse Events of Special Interest (AESI): Cardiovascular Events</title>
          <description>The incidence rate (IR) expressed as number of events per 100 patient-years of exposure (PYE).</description>
          <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
          <units>Events per 100 PYE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="493"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The IRs were estimated using a Poisson-mixture regression model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4007</p_value>
            <p_value_desc>Poisson-mixture regression was used to model the influence of age, stage of disease, and relevant medical history along with the treatment group effect on the number of events adjusted for individual study exposures measured in 100 PYE.</p_value_desc>
            <method>Wald test</method>
            <method_desc>The IRs for each treatment arm with 95% confidence interval (CI), and incidence rate ratio (IRRs) with 95% CI and p-values were based on Wald test.</method_desc>
            <param_type>IRR</param_type>
            <param_value>0.829</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.536</ci_lower_limit>
            <ci_upper_limit>1.283</ci_upper_limit>
            <estimate_desc>IRR for treatment with the lower 95% confidence limit &gt;1 suggest increased risk of AESI; upper confidence limit &lt;1 suggest decreased risk of AESI with the use of FIRMAGON. The limit including 1 suggests no difference b/w treatment groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of AESI: Decreased Bone Density</title>
        <description>IR of osteoporosis or osteopenia and bone fracture events are presented. The IR is expressed as number of events per 100 PYE.</description>
        <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
        <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
        <group_list>
          <group group_id="O1">
            <title>FIRMAGON</title>
            <description>FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label</description>
          </group>
          <group group_id="O2">
            <title>GnRH Agonist</title>
            <description>Any GnRH prescribed in accordance with the approved labels</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of AESI: Decreased Bone Density</title>
          <description>IR of osteoporosis or osteopenia and bone fracture events are presented. The IR is expressed as number of events per 100 PYE.</description>
          <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
          <units>Events per 100 PYE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="493"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Osteoporosis or Osteopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For osteoporosis and osteopenia events. The IRs were estimated using Poisson-mixture regression model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6710</p_value>
            <p_value_desc>Poisson-mixture regression was used to model the influence of age, stage of disease, and relevant medical history along with the treatment group effect on the number of events adjusted for individual study exposures measured in 100 PYE.</p_value_desc>
            <method>Wald test</method>
            <method_desc>The IRs for each treatment arm with 95% CI, and IRRs with 95% CI and p-values were based on Wald test.</method_desc>
            <param_type>IRR</param_type>
            <param_value>0.874</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.470</ci_lower_limit>
            <ci_upper_limit>1.626</ci_upper_limit>
            <estimate_desc>IRR for treatment with the lower 95% confidence limit &gt;1 suggest increased risk of AESI; upper confidence limit &lt;1 suggest decreased risk of AESI with the use of FIRMAGON. The limit including 1 suggests no difference b/w treatment groups.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For bone fracture events. The IRs were estimated using Poisson-mixture regression model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4544</p_value>
            <p_value_desc>Poisson-mixture regression was used to model the influence of age, stage of disease, and relevant medical history along with the treatment group effect on the number of events adjusted for individual study exposures measured in 100 PYE.</p_value_desc>
            <method>Wald test</method>
            <method_desc>The IRs for each treatment arm with 95% CI, and IRRs with 95% CI and p-values were based on Wald test.</method_desc>
            <param_type>IRR</param_type>
            <param_value>1.857</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.367</ci_lower_limit>
            <ci_upper_limit>9.403</ci_upper_limit>
            <estimate_desc>IRR for treatment with the lower 95% confidence limit &gt;1 suggest increased risk of AESI; upper confidence limit &lt;1 suggest decreased risk of AESI with the use of FIRMAGON. The limit including 1 suggests no difference b/w treatment groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of AESI: Glucose Intolerance or Type 2 Diabetes Mellitus (T2DM)</title>
        <description>IR of new onset or exacerbation of glucose intolerance or T2DM were presented. The IR expressed as number of events per 100 PYE.
Glucose intolerance events were defined as events of levels of fasting glucose of 6.1 to 6.9 mmol/L</description>
        <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
        <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
        <group_list>
          <group group_id="O1">
            <title>FIRMAGON</title>
            <description>FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label</description>
          </group>
          <group group_id="O2">
            <title>GnRH Agonist</title>
            <description>Any GnRH prescribed in accordance with the approved labels</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of AESI: Glucose Intolerance or Type 2 Diabetes Mellitus (T2DM)</title>
          <description>IR of new onset or exacerbation of glucose intolerance or T2DM were presented. The IR expressed as number of events per 100 PYE.
Glucose intolerance events were defined as events of levels of fasting glucose of 6.1 to 6.9 mmol/L</description>
          <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
          <units>Events per 100 PYE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="493"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose intolerance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3"/>
                    <measurement group_id="O2" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2DM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For glucose intolerance. The IRs were estimated using Poisson-mixture regression model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2529</p_value>
            <p_value_desc>Poisson mixture regression was used to model the influence of age, stage of disease, and history of diabetes mellitus along with the treatment group effect on the number of events adjusted for individual study exposures measured in 100 PYE.</p_value_desc>
            <method>Wald test</method>
            <method_desc>The IRs for each treatment arm with 95% CI, and IRRs with 95% CI and p-values were based on Wald test.</method_desc>
            <param_type>IRR</param_type>
            <param_value>1.193</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.882</ci_lower_limit>
            <ci_upper_limit>1.613</ci_upper_limit>
            <estimate_desc>IRR for treatment with the lower 95% confidence limit &gt;1 suggest increased risk of AESI; upper confidence limit &lt;1 suggest decreased risk of AESI with the use of FIRMAGON. The limit including 1 suggests no difference b/w treatment groups.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For T2DM. The IRs were estimated using Poisson-mixture regression model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0208</p_value>
            <p_value_desc>Poisson-mixture regression is used to model the influence of age, stage of disease, and relevant medical history along with the treatment group effect on the number of events adjusted for individual trial exposures measured in 100 PYE.</p_value_desc>
            <method>Wald test</method>
            <method_desc>The IRs for each treatment arm with 95% CI, and IRRs with 95% CI and p-values were based on Wald test.</method_desc>
            <param_type>IRR</param_type>
            <param_value>2.623</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.158</ci_lower_limit>
            <ci_upper_limit>5.944</ci_upper_limit>
            <estimate_desc>IRR for treatment with the lower 95% confidence limit &gt;1 suggest increased risk of AESI; upper confidence limit &lt;1 suggest decreased risk of AESI with the use of FIRMAGON. The limit including 1 suggests no difference b/w treatment groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hepatic Enzymes</title>
        <description>Change from baseline in hepatic enzyme levels (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and alkaline phosphatase [ALP]) are presented.</description>
        <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
        <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
        <group_list>
          <group group_id="O1">
            <title>FIRMAGON</title>
            <description>FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label</description>
          </group>
          <group group_id="O2">
            <title>GnRH Agonist</title>
            <description>Any GnRH Agonist prescribed in accordance with the approved labels</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hepatic Enzymes</title>
          <description>Change from baseline in hepatic enzyme levels (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and alkaline phosphatase [ALP]) are presented.</description>
          <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="493"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT (Visit 2, Month 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="302"/>
                    <count group_id="O2" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-70" upper_limit="63"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-19" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Visit 3, Month 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="272"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-65" upper_limit="174"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-41" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Visit 4, Month 9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-66" upper_limit="55"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-22" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Visit 5, Month 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-63" upper_limit="57"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-38" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Visit 6, Month 15)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-69" upper_limit="30"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-44" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Visit 7, Month 18)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-68" upper_limit="41"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-26" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Visit 8, Month 21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-70" upper_limit="204"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-25" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Visit 9, Month 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-65" upper_limit="332"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-24" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Visit 10, Month 30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="151"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-80" upper_limit="28"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-23" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Visit 11, Month 36)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-50" upper_limit="317"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-16" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Visit 12, Month 42)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-35" upper_limit="31"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-44" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Visit 13, Month 48)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-36" upper_limit="97"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-45" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Visit 14, Month 54)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-53" upper_limit="32"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-32" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Visit 15, end of trial [EOT], Month 60)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-30" upper_limit="33"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-16" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 2, Month 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-661" upper_limit="738"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-632" upper_limit="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 3, Month 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                    <count group_id="O2" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-990" upper_limit="979"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-649" upper_limit="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 4, Month 9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                    <count group_id="O2" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1009" upper_limit="1024"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-658" upper_limit="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 5, Month 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1029" upper_limit="614"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-661" upper_limit="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 6, Month 15)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-1027" upper_limit="957"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-225" upper_limit="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 7, Month 18)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-1031" upper_limit="475"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-217" upper_limit="889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 8, Month 21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="156"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-539" upper_limit="777"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-197" upper_limit="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 9, Month 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-756" upper_limit="307"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-228" upper_limit="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 10, Month 30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-540" upper_limit="300"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-211" upper_limit="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 11, Month 36)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-764" upper_limit="748"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-185" upper_limit="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 12, Month 42)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-773" upper_limit="1238"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-182" upper_limit="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 13, Month 48)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-785" upper_limit="657"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-204" upper_limit="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 14, Month 54)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-779" upper_limit="79"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-197" upper_limit="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (Visit 15 [EOT], Month 60)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" lower_limit="-756" upper_limit="164"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-157" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 2, Month 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-72" upper_limit="64"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-82" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 3, Month 9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                    <count group_id="O2" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-73" upper_limit="79"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-74" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 4, Month 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-68" upper_limit="69"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-41" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 5, Month 15)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-72" upper_limit="44"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-77" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 6, Month 15)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-73" upper_limit="194"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-78" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 7, Month 18)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-72" upper_limit="108"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-37" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 8, Month 21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-73" upper_limit="25"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-45" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 9, Month 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-75" upper_limit="68"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-43" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 10, Month 30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-73" upper_limit="28"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-46" upper_limit="665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 11, Month 36)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-72" upper_limit="57"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-43" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 12, Month 40)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-70" upper_limit="21"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-53" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 13, Month 48)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-70" upper_limit="167"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-52" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 14, Month 54)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-68" upper_limit="34"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-48" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (Visit 15 [EOT], Month 60)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-35" upper_limit="22"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-42" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hepatic Enzymes</title>
        <description>Change from baseline in hepatic enzyme level (bilirubin) is presented.</description>
        <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
        <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
        <group_list>
          <group group_id="O1">
            <title>FIRMAGON</title>
            <description>FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label</description>
          </group>
          <group group_id="O2">
            <title>GnRH Agonist</title>
            <description>Any GnRH prescribed in accordance with the approved labels</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hepatic Enzymes</title>
          <description>Change from baseline in hepatic enzyme level (bilirubin) is presented.</description>
          <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
          <units>umol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="493"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2, Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-169" upper_limit="97"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-108" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-234" upper_limit="216"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-16" upper_limit="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4, Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-233" upper_limit="38"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-18" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-98" upper_limit="113"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-285" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6, Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-22" upper_limit="166"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-23" upper_limit="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-99" upper_limit="111"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-28" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8, Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-200" upper_limit="145"/>
                    <measurement group_id="O2" value="-1.1" lower_limit="-287" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-196" upper_limit="141"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-113" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10, Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-199" upper_limit="14"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-282" upper_limit="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11, Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" lower_limit="-200" upper_limit="137"/>
                    <measurement group_id="O2" value="-3.2" lower_limit="-282" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12, Month 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-196" upper_limit="129"/>
                    <measurement group_id="O2" value="-1.7" lower_limit="-112" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13, Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-192" upper_limit="58"/>
                    <measurement group_id="O2" value="-1.9" lower_limit="-286" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14, Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-98" upper_limit="145"/>
                    <measurement group_id="O2" value="-1.9" lower_limit="-286" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 15 (EOT), Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-101" upper_limit="14"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-286" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Glucose</title>
        <description>Change from baseline in serum glucose are presented.</description>
        <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
        <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
        <group_list>
          <group group_id="O1">
            <title>FIRMAGON</title>
            <description>FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label</description>
          </group>
          <group group_id="O2">
            <title>GnRH Agonist</title>
            <description>Any GnRH agonist prescribed in accordance with the approved labels</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Glucose</title>
          <description>Change from baseline in serum glucose are presented.</description>
          <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="493"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2, Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-5" upper_limit="9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6" upper_limit="4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-11" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4, Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-7" upper_limit="14"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-7" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-8" upper_limit="6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-14" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6, Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6" upper_limit="5"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-8" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-8" upper_limit="3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-13" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8, Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-9" upper_limit="5"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-12" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6" upper_limit="4"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-4" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10, Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6" upper_limit="4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-8" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11, Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6" upper_limit="4"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12, Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-6" upper_limit="4"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-4" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13, Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-3" upper_limit="8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-6" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14, Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-5" upper_limit="3"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-10" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 15 (EOT), Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-1" upper_limit="9"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-10" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Classification of New Adverse Drug Reactions (ADRs)</title>
        <description>An ADR was defined as an AE assessed by investigator as possibly/probably related to the investigational product. Any new potentially unrecognized ADRs were presented.</description>
        <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
        <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
        <group_list>
          <group group_id="O1">
            <title>FIRMAGON</title>
            <description>FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label</description>
          </group>
          <group group_id="O2">
            <title>GnRH Agonist</title>
            <description>Any GnRH agonist prescribed in accordance with the approved labels</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Classification of New Adverse Drug Reactions (ADRs)</title>
          <description>An ADR was defined as an AE assessed by investigator as possibly/probably related to the investigational product. Any new potentially unrecognized ADRs were presented.</description>
          <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
          <units>New ADR</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="493"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long Term Evaluation of Clinical Evolution of Prostate Cancer</title>
        <description>Change in prostate specific antigen (PSA) is presented.</description>
        <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
        <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
        <group_list>
          <group group_id="O1">
            <title>FIRMAGON</title>
            <description>FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label</description>
          </group>
          <group group_id="O2">
            <title>GnRH Agonist</title>
            <description>Any GnRH prescribed in accordance with the approved labels</description>
          </group>
        </group_list>
        <measure>
          <title>Long Term Evaluation of Clinical Evolution of Prostate Cancer</title>
          <description>Change in prostate specific antigen (PSA) is presented.</description>
          <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="493"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2, Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="709"/>
                    <count group_id="O2" value="348"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.1" lower_limit="-788" upper_limit="297"/>
                    <measurement group_id="O2" value="-10.7" lower_limit="-438" upper_limit="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="657"/>
                    <count group_id="O2" value="358"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.1" lower_limit="-789" upper_limit="161"/>
                    <measurement group_id="O2" value="-11.4" lower_limit="-466" upper_limit="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4, Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="625"/>
                    <count group_id="O2" value="326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.0" lower_limit="-788" upper_limit="583"/>
                    <measurement group_id="O2" value="-11.5" lower_limit="-477" upper_limit="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="575"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.5" lower_limit="-787" upper_limit="578"/>
                    <measurement group_id="O2" value="-12.9" lower_limit="-465" upper_limit="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6, Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="526"/>
                    <count group_id="O2" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8" lower_limit="-783" upper_limit="493"/>
                    <measurement group_id="O2" value="-11.0" lower_limit="-472" upper_limit="648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="499"/>
                    <count group_id="O2" value="304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0" lower_limit="-770" upper_limit="665"/>
                    <measurement group_id="O2" value="-11.3" lower_limit="-477" upper_limit="790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8, Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="450"/>
                    <count group_id="O2" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" lower_limit="-770" upper_limit="201"/>
                    <measurement group_id="O2" value="-11.0" lower_limit="-485" upper_limit="567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0" lower_limit="-770" upper_limit="325"/>
                    <measurement group_id="O2" value="-11.9" lower_limit="-442" upper_limit="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10, Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="395"/>
                    <count group_id="O2" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.6" lower_limit="-770" upper_limit="692"/>
                    <measurement group_id="O2" value="-11.7" lower_limit="-488" upper_limit="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11, Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="352"/>
                    <count group_id="O2" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.4" lower_limit="-770" upper_limit="410"/>
                    <measurement group_id="O2" value="-11.4" lower_limit="-485" upper_limit="590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12, Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="309"/>
                    <count group_id="O2" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" lower_limit="-770" upper_limit="548"/>
                    <measurement group_id="O2" value="-10.5" lower_limit="-486" upper_limit="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13, Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="270"/>
                    <count group_id="O2" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.1" lower_limit="-770" upper_limit="487"/>
                    <measurement group_id="O2" value="-9.5" lower_limit="-484" upper_limit="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14, Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0" lower_limit="-770" upper_limit="204"/>
                    <measurement group_id="O2" value="-8.9" lower_limit="-482" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 15 (EOT), Month 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.7" lower_limit="-770" upper_limit="405"/>
                    <measurement group_id="O2" value="-9.0" lower_limit="-407" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Testosterone Levels</title>
        <description>Change from baseline in testosterone levels are presented.</description>
        <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
        <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
        <group_list>
          <group group_id="O1">
            <title>FIRMAGON</title>
            <description>FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label</description>
          </group>
          <group group_id="O2">
            <title>GnRH Agonist</title>
            <description>Any GnRH agonist prescribed in accordance with the approved labels</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Testosterone Levels</title>
          <description>Change from baseline in testosterone levels are presented.</description>
          <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="493"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2, Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" lower_limit="-38" upper_limit="33"/>
                    <measurement group_id="O2" value="-3.0" lower_limit="-10" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" lower_limit="-38" upper_limit="17"/>
                    <measurement group_id="O2" value="-3.3" lower_limit="-19" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4, Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" lower_limit="-38" upper_limit="53"/>
                    <measurement group_id="O2" value="-3.190" lower_limit="-10.16" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" lower_limit="-38" upper_limit="9"/>
                    <measurement group_id="O2" value="-3.236" lower_limit="-9.79" upper_limit="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6, Month 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" lower_limit="-38" upper_limit="10"/>
                    <measurement group_id="O2" value="-3.146" lower_limit="-10.16" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7, Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" lower_limit="-22" upper_limit="35"/>
                    <measurement group_id="O2" value="-3.127" lower_limit="-9.79" upper_limit="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8, Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" lower_limit="-38" upper_limit="22"/>
                    <measurement group_id="O2" value="-3.175" lower_limit="-9.80" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9, Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" lower_limit="-37" upper_limit="19"/>
                    <measurement group_id="O2" value="-3.041" lower_limit="-9.80" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10, Month 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" lower_limit="-22" upper_limit="2"/>
                    <measurement group_id="O2" value="-2.847" lower_limit="-9.78" upper_limit="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11, Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" lower_limit="-22" upper_limit="2"/>
                    <measurement group_id="O2" value="-2.977" lower_limit="-9.78" upper_limit="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12, Month 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" lower_limit="-22" upper_limit="2"/>
                    <measurement group_id="O2" value="-2.835" lower_limit="-9.65" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13, Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.930" lower_limit="-22.00" upper_limit="10.78"/>
                    <measurement group_id="O2" value="-2.6" lower_limit="-10" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14, Month 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.380" lower_limit="-22.23" upper_limit="7.35"/>
                    <measurement group_id="O2" value="-2.463" lower_limit="-9.61" upper_limit="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 15 (EOT), Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.870" lower_limit="-22.23" upper_limit="1.61"/>
                    <measurement group_id="O2" value="-2.2" lower_limit="-8" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause of Mortality</title>
        <description>A summary of IRs of all-cause mortality is presented.</description>
        <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
        <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
        <group_list>
          <group group_id="O1">
            <title>FIRMAGON</title>
            <description>FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label</description>
          </group>
          <group group_id="O2">
            <title>GnRH Agonist</title>
            <description>Any GnRH agonist prescribed in accordance with the approved labels</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause of Mortality</title>
          <description>A summary of IRs of all-cause mortality is presented.</description>
          <population>The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</population>
          <units>Events per 100 PYE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="493"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analyses of all-cause mortality was based on logistic regressions.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0821</p_value>
            <p_value_desc>A logistic regression was used to model the influence of age, stage of disease and relevant medical history along with the treatment group on the time to event for all-cause mortality.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression was used to model the influence of age, stage of disease and relevant medical history along with the treatment group.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.747</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.537</ci_lower_limit>
            <ci_upper_limit>1.038</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)</time_frame>
      <desc>An AE was defined as any untoward medical occurrence in a subject participating in a clinical investigation who received a pharmaceutical product.
The safety analysis set comprised of all subjects treated with at least one dose of medicinal product. The data was restricted to main treatment period (from signing of informed consent and administration of first dose until loss to follow-up, change/discontinuation in ADT, or end-of-study visit, whatever came first).</desc>
      <group_list>
        <group group_id="E1">
          <title>FIRMAGON</title>
          <description>FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label</description>
        </group>
        <group group_id="E2">
          <title>GnRH Agonist</title>
          <description>Any GnRH agonist prescribed in accordance with the approved labels</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="1000"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="236" subjects_at_risk="1000"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="1000"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1000"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Subventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Rectal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="1000"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1000"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1000"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1000"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1000"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Echinococciasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Injection site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Periumbilical abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Severe acute respiratory syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Urinary retention postoperative</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Radiation proctitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Haematocrit dereased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Vertebral lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="41" subjects_affected="40" subjects_at_risk="1000"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of ureter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Bladder adenocarcinoma stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Gastrointestinal cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hormone-refractory prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Metastases to bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Neoplasm of thymus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Retroperitoneal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hypoaesthesis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Anterograde amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Loss of consciosness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Orthostatic intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Peripheral sensorimotor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1000"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Ureteric dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Kidney enlargement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Lower urinary tract symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Urethral disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Vesical fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Rectoprostatic fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyapnoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Thoracic haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Stevens-johnson syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Eye prosthesis insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Ileostomy closure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Medical induction of coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Nephrostomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="493"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="294" subjects_at_risk="1000"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="226" subjects_affected="100" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="90" subjects_affected="80" subjects_at_risk="1000"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="172" subjects_affected="166" subjects_at_risk="1000"/>
                <counts group_id="E2" events="92" subjects_affected="88" subjects_at_risk="493"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <phone>-/-</phone>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

